Pembrolizumab with olaparib and chemoradiation for
previously untreated limited-stage small-cell lung cancer [ID6412]
Awaiting development
Reference number: GID-TA11497
Expected publication date: TBC
Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during early August 2026 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately early October 2026.